Quarterly Financial Results
Bajaj Healthcare Q1 FY27 Results: Revenue Grows 11.3% YoY; EBITDA and PAT Rise on Strong Domestic API Performance
NSE
bajajhcare
BSE
539872
- Bajaj Healthcare Limited reported a healthy Q1 FY27 performance, driven by strong growth in its domestic API business and improved product mix.
- Revenue from operations increased 11.3% YoY to ₹165.6 crore, while EBITDA grew 16.4% YoY with margin expansion to 17.8%. Profit After Tax (PAT) rose 15.8% YoY to ₹13.7 crore.
- During the quarter, the company also achieved a key regulatory milestone for Cenobamate Tablets and expanded its regulatory filings in Europe, strengthening its long-term specialty pharmaceutical pipeline.Â
PRICE-SENSITIVE TRIGGER
Event: Bajaj Healthcare Limited announced its unaudited financial results for Q1 FY27 along with business and regulatory updates for the quarter ended 30 June 2026.
Type: Quarterly Financial Results
Impact: Positive
Immediate Effect: The company delivered double-digit revenue and earnings growth, supported by strong domestic API demand, margin expansion, and continued progress in regulatory approvals and product commercialization.Â
Metrics:
Key Financial Metrics:
- Revenue from Operations: ₹165.6 crore (+11.3% YoY, +8.2% QoQ)
- Gross Profit: ₹80.4 crore (+16.2% YoY)
- Gross Margin: 48.3% (vs 46.2% in Q1 FY26)
- EBITDA: ₹29.6 crore (+16.4% YoY, +15.3% QoQ)
- EBITDA Margin: 17.8% (vs 17.0% in Q1 FY26)
- PAT (Before Exceptional Items): ₹13.7 crore (+15.8% YoY, +31.8% QoQ)
- PAT Margin: 8.3% (vs 8.0% in Q1 FY26)
Segment Performance:
- Domestic API Revenue: ₹92.3 crore (+27.1% YoY, +6.2% QoQ)
- API Exports: ₹50.1 crore (-4.1% YoY, +29.9% QoQ)
- Formulations Revenue: ₹23.3 crore (-3.1% YoY, -15.8% QoQ)Â
Highlight:
- Domestic API sales surged 27.1% YoY, driving overall revenue growth and helping EBITDA margin improve to 17.8% through a stronger product mix and disciplined execution.
What Happened ?
Bajaj Healthcare started FY27 on a strong note, with broad-based improvement in profitability despite mixed segment performance. Strong domestic API demand offset temporary weakness in export APIs and formulations, while an improved product mix supported gross margin and EBITDA expansion.
Beyond financial performance, the company strengthened its specialty pharmaceutical pipeline by securing India’s first SEC recommendation for Cenobamate Tablets and increasing its regulatory filings for European markets through additional CEP applications.Â
key details
Business & Regulatory Updates
- Domestic API business recorded strong volume-led growth, with revenue increasing 27.1% YoY.
- API export sales declined slightly due to temporary geopolitical disruptions in West Asia but improved significantly on a sequential basis.
- Formulations business experienced temporary moderation, with management expecting normalization during the remainder of FY27.
- Became the first company in India to secure SEC recommendation for the manufacture and marketing of Cenobamate Tablets, a next-generation anti-seizure medicine for adult partial-onset seizures.
- Filed two additional CEP applications, taking cumulative CEP filings to 12.
- Eight CEPs have already been approved, while four remain under regulatory review, strengthening the company’s presence in regulated EU and UK pharmaceutical markets.
- The expanded state-of-the-art R&D Centre at Savli became operational, enhancing product development and process innovation capabilities.Â
Note:
- Management indicated that the formulations business faced temporary demand moderation during the quarter and expects business mix and performance to improve as FY27 progresses.
Risk Analysis
Summary:
- Bajaj Healthcare delivered healthy earnings growth supported by domestic API demand and operational efficiencies. However, export market uncertainties and temporary weakness in formulations remain key areas for investors to monitor.
Key Risks:
- API export business remains exposed to geopolitical disruptions in international markets.
- Formulations segment reported lower revenue during the quarter.
- Commercial success of Cenobamate Tablets depends on regulatory approvals and execution of commercialization plans.
- Continued expansion in regulated markets requires timely approval of pending CEP applications.
- Pharmaceutical manufacturing remains subject to regulatory compliance and product approval timelines.Â
Worst Case:
- If geopolitical disruptions continue, export demand weakens further, or commercialization of new specialty products is delayed, revenue growth and profitability could moderate in subsequent quarters.
Risk Level: Medium
Company Commentary
- Management stated that FY27 has commenced on a positive note with healthy growth across key financial parameters.
- Improved product mix contributed to gross margin expansion and stronger operational profitability.
- Domestic API business continued to benefit from healthy demand, while formulations are expected to normalize over the coming quarters.
- The operationalization of the expanded Savli R&D Centre strengthens innovation capabilities and supports future product development.
- Progress toward commercialization of Cenobamate Tablets reinforces the company’s strategy of building a differentiated specialty pharmaceutical portfolio.
- Management remains focused on delivering sustainable growth and creating long-term shareholder value.Â
Official Exchange Filing: Bajaj Healthcare Limited
